Arcturus Therapeutics (ARCT) Tops Q4 EPS by 63c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($0.32), $0.63 better than the analyst estimate of ($0.95). Revenue for the quarter came in at $33.99 million versus the consensus estimate of $42.54 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Schwab's May activity shows margin loans nearly double
• Aspire Biopharma to acquire automotive supplier for $30 million